Willingsford Ltd.

Willingsford Ltd. is a United Kingdom healthcare company based in Southampton that develops and supplies treatments for wounds and dermatological lesions. Its commercial identity is built around a technology platform it calls MPPT, which the company describes as acting via the skin and wound microbiome to support the immune system — a mechanism it labels "passive immunotherapy." The company's flagship human wound-care brands are Amicapsil and Amicapsil-SCI, while SertaSil is positioned for veterinary wound treatment. A Microbiome Supporting Soap extends the range into skin care for sensitive skin, including that of babies and toddlers. According to the company's own materials, Amicapsil and SertaSil are approved treatments for wounds and dermatological lesions in humans and animals, and are said to be effective in both immunocompetent and immunocompromised individuals, including people with spinal cord injury and diabetes. Willingsford states that the products normally close wounds fully, and that where an underlying cause such as osteomyelitis exists they can control the associated wound and soft-tissue infection. The company emphasises that MPPT is effective against antimicrobial-resistant infections without contributing to new resistance, and that it avoids the side-effects of antibiotics. It also highlights ease of use — combining with tap water and cotton, without plastics, antimicrobials or surfactants — suitability for telemedicine, non-toxicity, and a low environmental impact. Willingsford frames its offering against what it presents as the limitations of standard wound care. It cites a 2022 US FDA conclusion, following a two-year review, that wounds not healing spontaneously constitute an unmet medical need because of the lack of efficacy of standard treatments. It also references Wood et al. (2026) reporting that UK wound outcomes did not improve between 2017 and 2025, that 20% of wounds require hospitalisation, and that 45% of all wounds are more than three months old. The company further states that in the UK alone in 2026 approximately 615 tonnes of antibiotics will be used in wound treatment without clinical benefit, contributing to deteriorating human health and climate change. The company reports clinical validation for its lead product, including two clinical studies confirming Amicapsil's effect on pressure injuries in spinal cord injury, with both studies finding 100% closure rates for acute and chronic pressure injuries. It also states that Amicapsil and Amicapsil-SCI have been accepted onto the NHS Supply Chain, a significant route to the UK public health market. Comparative claims on its news pages assert that Amicapsil and SertaSil remove wound infection 60% quicker than antibiotics and antiseptics. Willingsford operates at the intersection of wound care, infection control and antimicrobial resistance (AMR) policy, positioning its microbiome-based approach as an alternative to conventional antimicrobials. Its dual human and veterinary focus, together with an NHS Supply Chain listing, defines its current commercial footprint. Ownership, founding details and financial information are not established by the available evidence.

Willingsford Ltd. is a United Kingdom company based in Southampton, identified in public data as a company in that city. Its public-facing brand is Willingsford Healthcare, and its website presents a focused portfolio of wound-care and skin-care products built on a proprietary technology platform it calls MPPT. The company's narrative centres on the development of MPPT, described as a passive immunotherapy that acts via the skin and wound microbiome to support the immune system. From this platform Willingsford developed its flagship human wound-care products, Amicapsil and Amicapsil-SCI, and the veterinary product SertaSil. The company states that these are approved treatments for wounds and dermatological lesions in humans and animals, effective in both immunocompetent and immunocompromised individuals, including people with spinal cord injury and diabetes. It further states that the products normally close wounds fully and, where an underlying cause such as osteomyelitis is present, can control the associated wound and soft-tissue infection. A defining theme of Willingsford's history and positioning is the challenge of antimicrobial resistance. The company emphasises that MPPT is effective on antimicrobial-resistant infections and will not contribute to new resistance, and that it does not carry the side-effects of antibiotics. It also stresses practical and environmental advantages: MPPT is used in combination with tap water and cotton, without plastics, antimicrobials or surfactants, is non-toxic, is easy to use and is suitable for telemedicine, and will not affect the environment. Willingsford has sought to substantiate its claims through clinical evidence. Its news pages report two clinical studies confirming Amicapsil's effect on pressure injuries in spinal cord injury, with both studies finding 100% closure rates for acute and chronic pressure injuries. The company also reports that Amicapsil and Amicapsil-SCI have been accepted onto the NHS Supply Chain, giving the products a route into the UK public health system. Comparative claims state that Amicapsil and SertaSil remove wound infection 60% quicker than antibiotics and antiseptics. The company situates its work within a broader critique of standard wound care. It cites a 2022 US FDA conclusion, following a two-year review of the wound area, that wounds not healing spontaneously constitute an unmet medical need due to the lack of efficacy of standard treatments. It also references Wood et al. (2026), which reported that UK wound outcomes had not improved between 2017 and 2025, that 20% of wounds require hospitalisation, and that 45% of all wounds are more than three months old. Willingsford adds that in the UK alone in 2026 approximately 615 tonnes of antibiotics will be used in wound treatment without clinical benefit, contributing to deterioration in human health and climate change, and notes the direct costs of wounds to the UK. Beyond wound care, the company has extended its microbiome concept into skin care with a Microbiome Supporting Soap, described as ideal for sensitive skin, including the skin of babies and toddlers. Across its range, Willingsford presents a consistent identity: a UK healthcare innovator commercialising a non-antimicrobial, microbiome-based approach to wound healing in both human and veterinary markets. The available evidence does not establish the company's founding year, founders, ownership structure or financial details.

• US FDA concludes, following a two-year review of the wound area, that wounds not healing spontaneously constitute an unmet medical need due to lack of efficacy of standard treatments (cited by Willingsford).

• Wood et al. (2026) report that UK wound outcomes have not improved from 2017 to 2025, that 20% of wounds require hospitalisation, and that 45% of all wounds are more than 3 months old (cited by Willingsford).

• Willingsford reports that Amicapsil and Amicapsil-SCI have been accepted onto the NHS Supply Chain.

• Two clinical studies confirm Amicapsil's effect on pressure injuries in spinal cord injury, both finding 100% closure rates for acute and chronic pressure injuries.

Developer of MPPT-based, microbiome-immune-axis wound treatments positioned as antibiotic-free alternatives for human and veterinary wound care.

• Amicapsil

  Human wound and dermatological lesion treatment based on MPPT technology; effective in immunocompetent and immunocompromised individuals; accepted on NHS Supply Chain.

• Amicapsil-SCI

  Variant of Amicapsil for spinal cord injury-related pressure injuries; accepted on NHS Supply Chain.

• SertaSil

  MPPT-based treatment for veterinary wound care.

• Microbiome Supporting Soap

  Skin-care soap described as ideal for sensitive skin, including the skin of babies and toddlers.

1. 1Treatment for wounds and dermatological lesions - Willingsford Healthcarewillingsford.com
2. 2News - Willingsford Healthcarewillingsford.com
3. 3Contact - Willingsford Healthcarewillingsford.com
4. 4About - Willingsford Healthcarewillingsford.com
5. 5Willingsford Ltd. (United Kingdom) - Wikidatawikidata.org